317 related articles for article (PubMed ID: 33782530)
1. In vivo self-assembled small RNAs as a new generation of RNAi therapeutics.
Fu Z; Zhang X; Zhou X; Ur-Rehman U; Yu M; Liang H; Guo H; Guo X; Kong Y; Su Y; Ye Y; Hu X; Cheng W; Wu J; Wang Y; Gu Y; Lu SF; Wu D; Zen K; Li J; Yan C; Zhang CY; Chen X
Cell Res; 2021 Jun; 31(6):631-648. PubMed ID: 33782530
[TBL] [Abstract][Full Text] [Related]
2. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
[TBL] [Abstract][Full Text] [Related]
3. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
4. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
5. Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics.
Gangopadhyay S; Nikam RR; Gore KR
Nucleic Acid Ther; 2021 Aug; 31(4):245-270. PubMed ID: 33595381
[TBL] [Abstract][Full Text] [Related]
6. Centyrin ligands for extrahepatic delivery of siRNA.
Klein D; Goldberg S; Theile CS; Dambra R; Haskell K; Kuhar E; Lin T; Parmar R; Manoharan M; Richter M; Wu M; Mendrola Zarazowski J; Jadhav V; Maier MA; Sepp-Lorenzino L; O'Neil K; Dudkin V
Mol Ther; 2021 Jun; 29(6):2053-2066. PubMed ID: 33601052
[TBL] [Abstract][Full Text] [Related]
7. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
8. Direct cytoplasmic delivery of RNAi therapeutics through a non-lysosomal pathway for enhanced gene therapy.
Zhou J; Zhang J; Chen S; Lin Q; Zhu R; Wang L; Chen X; Li J; Yang H
Acta Biomater; 2023 Oct; 170():401-414. PubMed ID: 37625679
[TBL] [Abstract][Full Text] [Related]
9. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
10. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates.
Brown KM; Nair JK; Janas MM; Anglero-Rodriguez YI; Dang LTH; Peng H; Theile CS; Castellanos-Rizaldos E; Brown C; Foster D; Kurz J; Allen J; Maganti R; Li J; Matsuda S; Stricos M; Chickering T; Jung M; Wassarman K; Rollins J; Woods L; Kelin A; Guenther DC; Mobley MW; Petrulis J; McDougall R; Racie T; Bombardier J; Cha D; Agarwal S; Johnson L; Jiang Y; Lentini S; Gilbert J; Nguyen T; Chigas S; LeBlanc S; Poreci U; Kasper A; Rogers AB; Chong S; Davis W; Sutherland JE; Castoreno A; Milstein S; Schlegel MK; Zlatev I; Charisse K; Keating M; Manoharan M; Fitzgerald K; Wu JT; Maier MA; Jadhav V
Nat Biotechnol; 2022 Oct; 40(10):1500-1508. PubMed ID: 35654979
[TBL] [Abstract][Full Text] [Related]
11. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
Traber GM; Yu AM
J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in siRNA delivery.
Sarisozen C; Salzano G; Torchilin VP
Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
[TBL] [Abstract][Full Text] [Related]
13. RNA interference: the molecular immune system.
Bagasra O; Prilliman KR
J Mol Histol; 2004 Aug; 35(6):545-53. PubMed ID: 15614608
[TBL] [Abstract][Full Text] [Related]
14. Liver cancer cells as the model for developing liver-targeted RNAi therapeutics.
Hou B; Qin L; Huang L
Biochem Biophys Res Commun; 2023 Feb; 644():85-94. PubMed ID: 36640667
[TBL] [Abstract][Full Text] [Related]
15. Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury.
Marinho HS; Marcelino P; Soares H; Corvo ML
Curr Pharm Des; 2018; 24(23):2692-2700. PubMed ID: 30084326
[TBL] [Abstract][Full Text] [Related]
16. Noncoding RNA for Cancer Gene Therapy.
Zhong X; Zhang D; Xiong M; Zhang L
Recent Results Cancer Res; 2016; 209():51-60. PubMed ID: 28101687
[TBL] [Abstract][Full Text] [Related]
17. To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors.
Salim L; Desaulniers JP
Nucleic Acid Ther; 2021 Feb; 31(1):21-38. PubMed ID: 33121373
[TBL] [Abstract][Full Text] [Related]
18. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma.
Michiue H; Eguchi A; Scadeng M; Dowdy SF
Cancer Biol Ther; 2009 Dec; 8(23):2306-13. PubMed ID: 19901546
[TBL] [Abstract][Full Text] [Related]
19. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Mangala LS; Rodriguez-Aguayo C; Bayraktar E; Jennings NB; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2021; 2372():157-168. PubMed ID: 34417750
[TBL] [Abstract][Full Text] [Related]
20. A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells.
Hung CF; Lu KC; Cheng TL; Wu RH; Huang LY; Teng CF; Chang WT
Biochem Biophys Res Commun; 2006 Aug; 346(3):707-20. PubMed ID: 16793020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
